Case-Based Learning: Building a Differential Framework for Recurrent Fever With Nonspecific Findings

Abstract

Recurrent fever accompanied by nonspecific findings presents a significant diagnostic challenge for clinicians. The broad differential necessitates a systematic, case-based approach to identify underlying etiologies, ranging from infectious, autoinflammatory, malignant, to miscellaneous causes. This review distills current evidence, integrates recent guidelines, and synthesizes practical frameworks to support clinicians in navigating recurrent fever cases. Emphasis is placed on epidemiological trends, mechanistic insights, risk stratification, diagnostic algorithms, and management options, including emerging therapies and expert recommendations. The article provides actionable clinical pearls aimed at improving diagnostic accuracy and patient outcomes in this complex clinical scenario.

Introduction

Recurrent fever with nonspecific clinical findings remains a frequent yet vexing presentation in both hospital and outpatient settings. While fever is a cardinal sign of systemic disease, its episodic recurrence, in the absence of clear localizing features, complicates the diagnostic process. This clinical scenario is particularly important for healthcare professionals, given the potential for both missed diagnoses and unnecessary investigations. The utility of a structured, case-based differential framework is underscored by the breadth of possible causes, encompassing infectious, autoimmune, autoinflammatory, neoplastic, and other rare etiologies. This review aims to provide a comprehensive, evidence-based guide to the evaluation and management of recurrent fever with nonspecific findings, tailored for the needs of physicians and advanced practitioners.

Epidemiology / Disease Burden

Recurrent fever affects all age groups but is particularly prevalent in pediatric populations, immunocompromised hosts, and individuals with underlying chronic conditions. Population-based studies indicate that periodic fever syndromes, such as PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis), account for a notable proportion of recurrent fevers in children. In adults, the differential expands further, with infectious, neoplastic, and rheumatologic diseases taking precedence. The burden of recurrent fever is compounded by its impact on healthcare utilization, with repeated hospital visits, extensive laboratory workups, and increased patient and caregiver anxiety. Epidemiological surveillance also highlights regional variations, influenced by endemic infectious diseases, genetic predispositions, and healthcare access.

Pathophysiology

The pathophysiological basis of recurrent fever is multifactorial. Infectious etiologies may involve latent pathogens with intermittent reactivation (e.g., tuberculosis, malaria, Epstein-Barr virus). Autoinflammatory syndromes are driven by dysregulation of innate immunity, with aberrant inflammasome activation leading to periodic cytokine surges. Autoimmune conditions manifest recurrent fevers via adaptive immune dysregulation and immune complex deposition. Malignancies, particularly lymphomas and leukemias, can produce fever through tumor-mediated cytokine release and paraneoplastic phenomena. In some cases, environmental or exogenous triggers (e.g., drug reactions, factitious fever) must be considered as part of the mechanistic framework.

Risk Factors

Risk stratification is essential for refining the differential diagnosis. Key risk factors include age (e.g., younger age for hereditary autoinflammatory syndromes), epidemiological exposures (e.g., travel, occupational hazards), immunosuppression, family history of periodic fever syndromes, and underlying comorbidities such as autoimmune disease or malignancy. The presence of constitutional symptoms, organomegaly, lymphadenopathy, or abnormal laboratory markers further guides risk assessment and prioritization of diagnostic possibilities.

Clinical Features

Recurrent fever is typically defined as three or more episodes of fever within a six-month period, separated by periods of baseline health. Nonspecific findings may include malaise, arthralgia, myalgia, weight loss, rash, or mild laboratory abnormalities such as elevated inflammatory markers. The temporal pattern (e.g., regularity, duration, response to antipyretics), associated symptoms, and family history are critical for clinical characterization. Certain periodic fever syndromes manifest with stereotypical features during febrile episodes, such as aphthous ulcers or pharyngitis in PFAPA, while others, like familial Mediterranean fever, may present with serositis or erysipelas-like erythema.

Diagnosis

Diagnostic evaluation should be guided by a stepwise, evidence-based algorithm. Initial investigations typically include complete blood count, inflammatory markers (CRP, ESR), liver and renal function tests, and cultures as indicated. Imaging modalities (chest X-ray, abdominal ultrasound, CT/MRI) are employed based on clinical suspicion. Serological and molecular tests may be used to identify infectious, autoimmune, or autoinflammatory causes. In select cases, genetic testing is warranted for hereditary periodic fever syndromes. Bone marrow biopsy or lymph node excision may be necessary if malignancy is suspected. Importantly, the diagnostic approach should balance thoroughness with judicious test selection to avoid unnecessary interventions.

Treatment & Management

Management strategies are etiology-specific. Infectious causes are treated with targeted antimicrobials. Autoinflammatory syndromes often respond to colchicine (e.g., familial Mediterranean fever), corticosteroids, or biologics targeting interleukin-1 or TNF pathways. Autoimmune etiologies may require immunosuppressive therapy. Supportive care, including antipyretics and hydration, is universally applicable. For patients with no identifiable cause (fever of unknown origin), close monitoring and periodic reassessment are recommended, with empirical therapy reserved for selected high-risk scenarios. Multidisciplinary collaboration incorporating rheumatology, infectious disease, hematology, and genetics is often needed for complex cases.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the understanding and management of recurrent fever syndromes. Next-generation sequencing has facilitated the identification of novel genetic mutations underlying monogenic autoinflammatory diseases. Biologic therapies, particularly IL-1 inhibitors (anakinra, canakinumab) and anti-TNF agents, have transformed the prognosis for patients with refractory periodic fever syndromes. Ongoing trials are evaluating Janus kinase inhibitors and other cytokine-targeted drugs. Artificial intelligence tools for pattern recognition in electronic health records are being explored to aid early diagnosis. These advances underscore the importance of precision medicine approaches in recurrent fever evaluation.

Guideline Recommendations

International guidelines (e.g., EULAR, ACR, IDSA) emphasize a systematic approach to recurrent fever, advocating for detailed history, physical examination, and judicious, stepwise investigations. Genetic testing should be considered in cases with early onset, family history, or suggestive clinical patterns. Empirical therapy is discouraged in the absence of clear etiology, except in life-threatening scenarios. Regular follow-up and patient education are integral to optimal management. Multidisciplinary teams and referral to specialized centers are recommended for complex or refractory cases.

Conclusion

Recurrent fever with nonspecific findings demands a structured, evidence-based approach to establish an accurate diagnosis and initiate appropriate therapy. Advances in genetic testing, biologic therapies, and clinical decision support systems are enhancing diagnostic and therapeutic capabilities. Clinicians should maintain a high index of suspicion for both common and rare etiologies, engage in multidisciplinary collaboration, and adhere to guideline-driven pathways to optimize patient outcomes in this challenging clinical context.